aTYR PHARMA (ATYR) Non-Current Deffered Revenue (2014 - 2016)
aTYR PHARMA's (ATYR) quarterly Non-Current Deffered Revenue came in at $49000.0 in Q1 2016, down 86.72% YoY from $369000.0 in Q2 2015, and down 62.31% on a QoQ basis from $130000.0 in Q4 2015.
aTYR PHARMA (ATYR) Non-Current Deffered Revenue (2014 - 2016) Analysis & Trends
aTYR PHARMA (ATYR) has 3 years of Non-Current Deffered Revenue data on file, last reported at $49000.0 in Q1 2016.
- Quarterly Non-Current Deffered Revenue fell 86.72% year-over-year to $49000.0 in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $49000.0 (down 86.72% YoY) and the FY2015 annual result came in at $130000.0, down 70.79% from the prior year.
- Non-Current Deffered Revenue declined to $49000.0 in Q1 2016, from $130000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $445000.0 in Q4 2014 to a low of $49000.0 in Q1 2016.
- A 3-year average of $249166.7 and a median of $251000.0 in 2015 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2015 — Non-Current Deffered Revenue sank 70.79% — and 2016, when it plunged 86.72%.
- Tracing ATYR's Non-Current Deffered Revenue over 3 years: stood at $445000.0 in 2014, then slumped by 70.79% to $130000.0 in 2015, then tumbled by 62.31% to $49000.0 in 2016.
- The last three Non-Current Deffered Revenue figures came in at $49000.0 (Q1 2016), $130000.0 (Q4 2015), and $211000.0 (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 49,000.00 |
| Dec 31, 2015 | 130,000.00 |
| Sep 30, 2015 | 211,000.00 |
| Jun 30, 2015 | 291,000.00 |
| Mar 31, 2015 | 369,000.00 |
| Dec 31, 2014 | 445,000.00 |